CCR7 / C-C chemokine receptor type 7 · Western blot design guide

Design a Western Blot for CCR7

Real validated CCR7 Western blot protocols, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-CCR7 WB antibodies. Everything you need to plan the experiment before you commit precious samples.

Evidence assembled September 2026 · For research use; verify linked source records and product datasheet before use
Western blot protocol sheet for CCR7: expected band ~42.9 kDa, hero antibody A00390, catalog values and labelled standard workflow; separate PMC comparisons on the guide
Printable CCR7 Western blot protocol sheet — expected band ~42.9 kDa, antibody A00390, controls and PMC citations. Open the full CCR7 WB guide →

CCR7 Western Blot Experimental Design Guide

Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before running
Expected band ~42.9 kDa
Gel 12–15% (standard starting point)
Positive control ⓘ Colon (IHC candidate; verify WB) +4 more
Negative control ⓘ Adipose tissue (IHC candidate; verify WB)
Important caveats
Reasons your observed band may differ from the expected size.
PTM Glycosylated + Cleaved
Caveat Glycosylation-state controls
Gene-set association MSigDB Hallmark membership
Isoform 1 isoform(s)
Section 1

Real Curated CCR7 Western Blot Protocols

The A00390 protocol combines labelled catalog values with standard starting conditions. Published comparisons retain their own sample, reagent and detection scope.

Recommended Western blot protocol parameters
Sample / lysatehuman spleen tissue lysate (catalog A00390)
Gel %12–15% (standard starting point)
Load20–30 µg total protein per lane; optimize for abundance (standard starting point)
TransferStandard semi-dry transfer; verify efficiency (standard starting point)
Membrane0.45 µm PVDF (standard starting point)
Blocking5% milk or 5% BSA in TBST (standard starting point)
Primary antibodyA00390 · 1 μg/ml (catalog A00390)
Primary incubationOvernight at 4 °C (standard starting point)
Secondary antibodySpecies-matched HRP conjugate at validated dilution (standard starting point)
Secondary incubation1 h at room temperature (standard starting point)
Wash3 × 5 min in TBST (standard starting point)
DetectionECL; bracket exposures to avoid saturation (standard starting point)
Section 2

What Is the Expected CCR7 Western Blot Band Size?

CCR7 has a predicted precursor mass of 42.9 kDa; signal peptide cleavage and Asn36 glycosylation may affect migration, but no empirical band size is supplied.

What am I looking at on my blot?
Band near 42.9 kDaConsistent with the predicted CCR7 precursor mass; identity needs confirmation.
Band below 42.9 kDaCould reflect removal of the 1–24 signal peptide; mature migration is not established.
Band above 42.9 kDaCould reflect N-linked glycosylation at Asn36; the size effect is not established.
Faint or absent band in lysateMembrane-localized CCR7 may be poorly recovered during extraction.
💡Expected CCR7 appearanceCCR7 has a predicted precursor mass of 42.9 kDa, but no empirical band size is supplied; confirm any candidate band with ordinary identity controls.
How each factor affects band size
Predicted precursor massProvides a 42.9 kDa reference, not a measured band position.
N-linked glycosylation at Asn36May increase apparent size if occupied; no shift is quantified.
Signal peptide at residues 1–24Its cleavage would make the mature chain smaller than the precursor.
Mature chain after signal peptide cleavageIts apparent size is not supplied and cannot be calculated from the feature alone.
Why is my band missing or off?
SituationLikely causeNext action
No band in lysateMembrane-localized CCR7 may be poorly extracted.Check membrane protein recovery and use a positive lysate control.
Band higher than expectedN-linked glycosylation at Asn36 is possible, but its effect is unproven.Compare treated and untreated samples and confirm band identity.
Band lower than expectedSignal peptide cleavage could reduce size.Check antibody epitope coverage and confirm identity with a second antibody.
Multiple bandsPrecursor processing or Asn36 glycosylation could contribute; distinct bands are not established.Compare glycosidase-treated samples and validate bands with a second antibody.
Weak or no signalRecovery or detection of this membrane receptor may be limited.Check extraction, loading, transfer and a positive control.

Sample controls for CCR7 Western blot

🧪HPA-IHC candidate guidance (verify in WB): For positive controls for CCR7 in Western blot, you can use lymph node tissue, which HPA rates as highly positive.
Positive control: Colon (IHC candidate; verify WB)
Negative control: Adipose tissue (IHC candidate; verify WB)
Loading controls: Run GAPDH, β-actin, and a total-protein stain such as Ponceau alongside the samples.
⚠️Feasibility: As a multi-pass membrane protein, CCR7 may be easier to detect in membrane-enriched lysate.

HPA tissue expression evidence for CCR7

Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.

Higher expression tissues · candidate positive controls from IHC

TissueCell typeLevelEvidenceSource
Colon endothelial cells High Protein (IHC) HPA →
Lung alveolar cells High Protein (IHC) HPA →
Lymph node non-germinal center cells High Protein (IHC) HPA →
Rectum peripheral nerve/ganglion High Protein (IHC) HPA →
Skin cells in corneal layer High Protein (IHC) HPA →

Lower expression tissues · IHC evidence, not confirmed WB-negative controls

TissueCell typeLevelEvidenceSource
Adipose tissue adipocytes Not detected Protein (IHC) HPA →
Adrenal gland glandular cells Not detected Protein (IHC) HPA →
Appendix endocrine cells Not detected Protein (IHC) HPA →
Breast adipocytes Not detected Protein (IHC) HPA →
Bronchus respiratory epithelial cells Not detected Protein (IHC) HPA →
Section 3

Advanced CCR7 Western Blot Tips

Deeper troubleshooting and optimisation questions for CCR7, answered from its protein features.

How should CCR7 band migration be interpreted?
Band shift · Use the separately labelled calculated mass and catalog-observed evidence above. A sequence annotation does not establish an observed migration shift. Verify target identity with orthogonal controls.
Do annotated CCR7 isoforms explain multiple bands?
Isoforms · The supplied features list one isoform and no alternative sequence. They therefore provide no specific isoform assignment for additional bands.
Which glycosylation site should be considered when assessing CCR7 bands?
PTM · UniProt annotates one N-linked glycosylation site at Asn36. This is UniProt sequence numbering; check the numbering convention before comparing it with an antibody or paper. The annotation does not predict the size of a band shift.
Does this guide establish induction of CCR7?
Induction · No general induction response is established by this guide. A pathway or gene-set association is not evidence of induction in a particular specimen. Verify the relevant treatment and control in a target-specific experiment.
How should transfer be checked for CCR7?
Transfer · Standard workflow guidance: verify transfer efficiency for the intended target size before interpreting a weak signal. Use total-protein assessment and optimize transfer for the membrane, gel and apparatus; the labelled catalog values take precedence.
How should blocking be optimized?
Blocking · Standard workflow guidance: follow the A00390 datasheet where specified. Otherwise compare 5% milk or 5% BSA in TBST; for a phospho-specific assay start with BSA. Optimize background and specific signal with matched controls.
How should CCR7 be quantified?
Quantitation · Standard workflow guidance: quantify only a validated target band within the linear exposure range. Use consistent sample preparation and loading, retain biological replicates, and avoid interpreting saturation or loading differences as regulation.
Why might CCR7 migrate differently from its predicted 42.9 kDa?
Interpretation · CCR7 has a signal peptide at residues 1..24 and an annotated N-linked glycosylation site at Asn36. Processing or glycosylation could affect migration, but these features alone do not establish a visible shift. No observed band position is supplied.

UniProt annotates a signal peptide at residues 1..24. Account for this segment when comparing the 42.9 kDa predicted mass with a processed protein, but do not assign a band based on this feature alone.

UniProt lists one disulfide bond. Compare samples prepared under reducing and nonreducing conditions if migration differs, while recognizing that the annotation alone does not establish a band shift.

CCR7 is annotated as a multi-pass cell-membrane protein. Use consistent membrane extraction and solubilization across samples so differences in recovery are less likely to be mistaken for differences in CCR7 abundance.

Compare the same candidate band across samples prepared with the same extraction and loading procedure. CCR7's multi-pass membrane location makes consistent recovery especially relevant to interpreting intensity differences.

Start with the 42.9 kDa predicted mass, then consider the annotated signal peptide at residues 1..24, N-linked Asn36, and one disulfide bond. None of these features alone identifies an unexpected band; the supplied evidence includes no observed CCR7 band position.
Boster reagents

CCR7 Western Blot Antibodies

Catalog antibodies with Western blot application and product-specific WB images. Evaluate suitability with the reported sample, controls and experimental conditions.

Real WB data Western blot analysis of CCR7 in human spleen tissue lysate with CCR7 antibody at 1 μg/ml.
Anti-C-C chemokine receptor type 7 CCR7 Antibody
Cat # A00390
Real WB data Western blot analysis of CCR7 using anti-CCR7 antibody (M00390). Electrophoresis was performed on a 5-20% SDS-PAGE gel at 70V (Stacking gel) / 90V (Resolving gel) for 2-3 hours. The sample well of each lane was loaded with 30 ug of sample under reducing conditions. Lane 1: human MCF-7 whole cell lysates, Lane 2: human K562 whole cell lysates, Lane 3: rat spleen tissue lysates, Lane 4: rat lung tissue lysates, Lane 5: rat C6 whole cell lysates, Lane 6: mouse spleen tissue lysates, Lane 7: mouse lung tissue lysates. After electrophoresis, proteins were transferred to a nitrocellulose membrane at 150 mA for 50-90 minutes. Blocked the membrane with 5% non-fat milk/TBS for 1.5 hour at RT. The membrane was incubated with rabbit anti-CCR7 antigen affinity purified monoclonal antibody (Catalog # M00390) at 1:500 overnight at 4°C, then washed with TBS-0.1%Tween 3 times with 5 minutes each and probed with a goat anti-rabbit IgG-HRP secondary antibody at a dilution of 1:500 for 1.5 hour at RT. The signal is developed using an Enhanced Chemiluminescent detection (ECL) kit (Catalog # EK1002) with Tanon 5200 system. A specific band was detected for CCR7 at approximately 43 kDa. The expected band size for CCR7 is at 43 kDa.
Anti-CCR7 Rabbit Monoclonal Antibody
Cat # M00390

Two the supplier anti-CCR7 antibodies have WB images: A00390 in human spleen lysate and M00390 in human cell, rat tissue and cell, and mouse tissue lysates. These images document the stated samples and conditions, not universal validation across each species.

Which to pick: For human spleen lysate, consider A00390 (tested at 1 μg/ml). For human MCF-7 or K562 cells, rat samples, or mouse spleen or lung, M00390 has matching WB examples (tested at 1:500).

Source: BosterBio CCR7 gene-info card — filtered to Western-blot-capable antibodies; each card shows that product's actual WB validation figure.